Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962517 | 0.99 | KMT2A (0.46) | KMT2AMEN1GAACACNA1FCACNA1D | |
| SCHEMBL1964650 | 0.92 | ALDH1A1 (0.48) | KDM4ETSHRALDH1A1HRH3 | |
| SCHEMBL15163090 | 0.91 | KMT2A (0.50) | KMT2AMEN1GAAKDM4EKDR | |
| SCHEMBL1961837 | 0.88 | KMT2A (0.55) | KMT2AMEN1GAAKDM4EKDR | |
| SCHEMBL1962514 | 0.87 | KMT2A (0.53) | KMT2AMEN1GAAKDM4EKDR | |
| SCHEMBL1963479 | 0.83 | CDC25B (0.54) | KMT2AGAAKDM4ETSHRALDH1A1 | |
| SCHEMBL1964675 | 0.83 | CDC25B (0.46) | KMT2AMEN1GAAKDM4EKDR | |
| SCHEMBL1961738 | 0.82 | CDC25B (0.45) | KMT2AMEN1GAAKDM4EKDR | |
| SCHEMBL14598477 | 0.81 | KDM4E (0.48) | KMT2AMEN1GAAKDM4EKDR | |
| SCHEMBL1964681 | 0.81 | PPARG (0.47) | KDM4ETSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919892-B1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8481568-B2 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SEPRACOR INC. | 2011-06-16 | — | — | US | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144158-A1 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SI, CYP3A5, CYP2D6 | KMT2A 4292/4885MEN1 907/4885GAA 1338/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | KMT2A 4292/4885MEN1 907/4885GAA 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.